[Remote] Medical Science Liaison - East Coast at Axsome Therapeutics Inc

Remote

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Stem Cell TherapyIndustries

Skills

Key technologies and capabilities for this role

RheumatologyClinical StudiesField-based roleKey Opinion Leader (KOL) engagementHealthcare professional relationship buildingClinical site engagementPatient community engagementAdvisory boardsInvestigator-initiated researchScientific collaborationTerritory planningMedical educationCell therapyClinical trialsScientific conferencesMedical congressesClinical OperationsRegulatory affairsPharmacovigilance

Questions & Answers

Common questions about this position

What qualifications are required for the Medical Science Liaison role?

Candidates need an advanced degree such as M.D., D.O., PharmD, or PhD in a medically related field, or a Master’s in health sciences with relevant experience. They also require 3+ years as a Medical Science Liaison or in Medical Affairs/Clinical Development, plus 1+ years in rheumatology and/or cell therapy.

Is this Medical Science Liaison position remote, and where is it based?

This is a remote position based from the U.S. East Coast.

What is the salary or compensation for this role?

This information is not specified in the job description.

What experience makes a strong candidate for this Medical Science Liaison position?

Strong candidates will have field-based experience building relationships with KOLs and healthcare professionals, plus demonstrated ability to work independently and collaboratively, with knowledge of US regulations and strong communication skills.

What key skills are needed for success in this role?

Key skills include excellence in communication, ability to establish and nurture relationships with KOLs and HCPs, and staying current with clinical data and publications.

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free